These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 18784126)

  • 1. Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis.
    Distler JH; Distler O
    Rheumatology (Oxford); 2008 Oct; 47 Suppl 5():v10-1. PubMed ID: 18784126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases?
    Beyer C; Distler JH; Distler O
    Swiss Med Wkly; 2010; 140():w13050. PubMed ID: 20419513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis.
    Akhmetshina A; Dees C; Pileckyte M; Maurer B; Axmann R; Jüngel A; Zwerina J; Gay S; Schett G; Distler O; Distler JH
    FASEB J; 2008 Jul; 22(7):2214-22. PubMed ID: 18326784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies.
    Distler JH; Distler O
    Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i48-51. PubMed ID: 19995744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials.
    Iwamoto N; Distler JH; Distler O
    Curr Rheumatol Rep; 2011 Feb; 13(1):21-7. PubMed ID: 21042889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib mesylate causes genome-wide transcriptional changes in systemic sclerosis fibroblasts in vitro.
    Hinchcliff M; Huang CC; Ishida W; Fang F; Lee J; Jafari N; Wilkes M; Bhattacharyya S; Leof E; Varga J
    Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S86-96. PubMed ID: 22691216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis.
    Akhmetshina A; Venalis P; Dees C; Busch N; Zwerina J; Schett G; Distler O; Distler JH
    Arthritis Rheum; 2009 Jan; 60(1):219-24. PubMed ID: 19116940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors.
    Maurer B; Distler A; Dees C; Khan K; Denton CP; Abraham D; Gay RE; Michel BA; Gay S; Hw Distler J; Distler O
    Ann Rheum Dis; 2013 Dec; 72(12):2039-46. PubMed ID: 24013728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines.
    Deguchi Y; Kimura S; Ashihara E; Niwa T; Hodohara K; Fujiyama Y; Maekawa T
    Leuk Res; 2008 Jun; 32(6):980-3. PubMed ID: 18191450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
    Distler JH; Jüngel A; Huber LC; Schulze-Horsel U; Zwerina J; Gay RE; Michel BA; Hauser T; Schett G; Gay S; Distler O
    Arthritis Rheum; 2007 Jan; 56(1):311-22. PubMed ID: 17195235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.
    Rix U; Hantschel O; Dürnberger G; Remsing Rix LL; Planyavsky M; Fernbach NV; Kaupe I; Bennett KL; Valent P; Colinge J; Köcher T; Superti-Furga G
    Blood; 2007 Dec; 110(12):4055-63. PubMed ID: 17720881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
    Pavey T; Hoyle M; Ciani O; Crathorne L; Jones-Hughes T; Cooper C; Osipenko L; Venkatachalam M; Rudin C; Ukoumunne O; Garside R; Anderson R
    Health Technol Assess; 2012; 16(42):iii-iv, 1-277. PubMed ID: 23134589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib and the treatment of fibrosis: recent trials and tribulations.
    Gordon J; Spiera R
    Curr Rheumatol Rep; 2011 Feb; 13(1):51-8. PubMed ID: 21086081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation.
    Loveman E; Cooper K; Bryant J; Colquitt JL; Frampton GK; Clegg A
    Health Technol Assess; 2012; 16(23):iii-xiii, 1-137. PubMed ID: 22564553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematology: Nilotinib and dasatinib--new 'magic bullets' for CML?
    Breccia M
    Nat Rev Clin Oncol; 2010 Oct; 7(10):557-8. PubMed ID: 20877419
    [No Abstract]   [Full Text] [Related]  

  • 16. Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation.
    Rogers G; Hoyle M; Thompson Coon J; Moxham T; Liu Z; Pitt M; Stein K
    Health Technol Assess; 2012; 16(22):1-410. PubMed ID: 22551803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined inhibition of c-Abl and PDGF receptors for prevention and treatment of murine sclerodermatous chronic graft-versus-host disease.
    Zerr P; Distler A; Palumbo-Zerr K; Tomcik M; Vollath S; Dees C; Egberts F; Tinazzi I; Del Galdo F; Distler O; Schett G; Spriewald BM; Distler JH
    Am J Pathol; 2012 Nov; 181(5):1672-80. PubMed ID: 22940072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Src tyrosine kinases in experimental pulmonary hypertension.
    Pullamsetti SS; Berghausen EM; Dabral S; Tretyn A; Butrous E; Savai R; Butrous G; Dahal BK; Brandes RP; Ghofrani HA; Weissmann N; Grimminger F; Seeger W; Rosenkranz S; Schermuly RT
    Arterioscler Thromb Vasc Biol; 2012 Jun; 32(6):1354-65. PubMed ID: 22516066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices.
    Kantarjian H; Cortes J
    J Natl Compr Canc Netw; 2008 Mar; 6 Suppl 2():S37-42; quiz S43-S44. PubMed ID: 18397680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of nilotinib, dasatinib and imatinib as first-line treatment for chronic myeloid leukemia in Colombia, 2012.
    Romero M; Chávez D; De Los Ríos M; Alvis-Guzmán N
    Biomedica; 2014; 34(1):48-59. PubMed ID: 24968906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.